Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca Growth Regulatory News (HYG)

Share Price Information for Seneca Growth (HYG)

Share Price is delayed by 15 minutes
Get Live Data
9.00    0.00 (0.00%)
Bid:
7.00
Ask:
11.00
Spread: 4.00 (57.143%)
Market Cap: £2.98m
HYG Live PriceLast checked at - London Stock Exchange

Intraday Seneca Growth Share Chart

Interim Management Statement

14 Nov 2008 13:08

RNS Number : 2059I
Hygea VCT plc
14 November 2008
 



14 November 2008

HYGEA VCT PLC

INTERIM MANAGEMENT STATEMENT FOR THE PERIOD ENDED 30 SEPTEMBER 2008

Hygea VCT plc presents its interim management statement for the period ended 30 September 2008.This constitutes the company's second interim management statement for the financial year ending 31 December 2008, as required by the UK Listing Authority's Disclosure and Transparency Rule 4.3. This statement has been prepared solely to provide additional information in order to meet the requirements of the Disclosure and Transparency Rules and should not be relied on by shareholders, or any other party, for any other purpose.

The unaudited net asset value per ordinary share and the number of shares in issue at 30 September 2008 were 61.5p and 7,788,191 respectively (30 June 2008: 60.1p and 7,682,191 respectively and at 31 December 2007: 61.2p and 7,530,191 respectively).

On 31 July 2008, a total of 106,000 new ordinary shares were allotted at a price of 50p pursuant to the 10% top-up offer announced on 19 March 2008.

During the three months ended 30 September 2008 the company made an additional investment of £35,000 in Scancell Limited on its listing on Plus Quoted. As previously reported the shareholding in Immunodiagnostic Holdings PLC was sold during the period for £35,000 realising a profit of some £10,000.

The directors are pleased to note a modest increase in the net asset value in the period. The increase has resulted from the uplift in carrying value of three investee companies and the realised gain on the sale of Immunodiagnostic Holdings PLC, offset by the decline in carrying value of one investee company, the decline in the value of the, albeit reduced, AIM portfolio as well as operating expenses in the period. The company will be eligible for repayment of VAT in respect of management fees for part of the period since the company was launched but it is not yet possible to quantify the benefit due to the Company, although it is unlikely to be significant. The directors remain confident that the portfolio will deliver value to shareholders over the three to five year period referred to in the annual report based on positive operating developments within the portfolio.

The directors are not aware of any events which have taken place between 30 September 2008 and the date of publication of this statement, which have had a material effect on the financial position of the company.

On 12th November 2008, the board appointed Mr Craig Hunter FCIS as Company Secretary.

Enquiries: 

James Otter, Hygea vct plc - james.otter@ellipson.co.uk 

Charles Breese, Hygea VCT plc on 01280 703482 or larpentnewton@btinternet.com

website: www.hygeavct.com

Roland Cornish, Beaumont Cornish Limited on 020 7628 3396

14 November 2008.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUSRORWNRAAAA
Date   Source Headline
18th May 20231:38 pmGNWDirectorate Changes
18th May 20231:32 pmGNWResults of Annual General Meeting Voting
3rd May 20234:01 pmGNWIssue of Equity and Total Voting Rights
27th Apr 202311:25 amGNWPublication of a Supplementary Prospectus
21st Apr 20237:00 amGNWFinal Results for the Year Ended 31 December 2022
5th Apr 20233:05 pmGNWIssue of Equity and Total Voting Rights
4th Apr 20237:00 amGNWNet Asset Value(s)
7th Mar 20231:30 pmGNWInterim Dividend Declarations
21st Dec 20227:00 amGNWB Share Portfolio Update
7th Dec 20227:00 amGNWOrdinary Share NAV Update and Dividend Declaration
30th Nov 202212:33 pmGNWDirector/PDMR Shareholding
30th Nov 202212:29 pmGNWIssue of Equity and Total Voting Rights
19th Oct 20227:00 amGNWSecond Interim Dividend on B Shares
13th Oct 20227:00 amGNWNAV Update
26th Aug 202211:56 amGNWOffer for Subscription and Publication of Prospectus
22nd Aug 20222:53 pmGNWPDMR Shareholding
22nd Aug 20222:46 pmGNWIssue of Equity and Total Voting Rights
16th Aug 20227:00 amGNWB Share Closure of Offer for Subscription
15th Jul 20227:00 amGNWHalf-year report
30th Jun 202210:17 amGNWIssue of Supplementary Prospectus
23rd May 20227:00 amGNWAppointment of Auditor
23rd May 20227:00 amGNWShare Buy-back and TVR
4th May 202211:25 amGNWIssue of Equity and Total Voting Rights
27th Apr 20223:42 pmGNWResult of AGM
5th Apr 20221:56 pmGNWIssue of Equity and Total Voting Rights
1st Apr 20221:43 pmGNWIssue of Equity and Total Voting Rights
1st Apr 202211:05 amGNWNAV Update
25th Mar 202210:00 amGNWIssue of Supplementary Prospectus
25th Mar 20227:01 amGNWNAV Update
25th Mar 20227:00 amGNWFinal Results for the Year Ended 31 December 2021
8th Mar 20227:00 amGNWInterim Dividend on B Shares
10th Dec 202111:40 amGNWDirector/PDMR Shareholding
8th Dec 20213:24 pmGNWIssue of Equity and Total Voting Rights
16th Nov 20217:00 amGNWSecond Interim Dividend on B Shares
29th Oct 202111:42 amGNWOffer for Subscription and Publication of Prospectus
28th Oct 20211:06 pmGNWTR-1: Notification of major holdings
21st Oct 20219:01 amGNWNAV Update
16th Sep 202112:16 pmRNSSecond Price Monitoring Extn
16th Sep 202112:14 pmRNSPrice Monitoring Extension
14th Sep 20212:07 pmRNSSecond Price Monitoring Extn
14th Sep 20212:01 pmRNSPrice Monitoring Extension
25th Aug 20214:41 pmRNSSecond Price Monitoring Extn
25th Aug 20214:36 pmRNSPrice Monitoring Extension
12th Aug 20214:42 pmRNSSecond Price Monitoring Extn
12th Aug 20214:38 pmRNSPrice Monitoring Extension
26th Jul 20217:00 amGNWHalf-year report
15th Jun 202112:18 pmGNWIssue of Equity and Total Voting Rights
15th Jun 20217:00 amGNWB Share Net Asset Value
3rd Jun 202110:51 amGNWInterim Capital Dividend on Ordinary Shares
20th May 20217:00 amGNWB Share Extension of Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.